BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

March 27, 2018

Primary Completion Date

May 18, 2020

Study Completion Date

May 18, 2020

Conditions
Colitis, Ulcerative
Interventions
DRUG

Spesolimab

Solution for infusion

DRUG

Placebo

Solution for infusion

Trial Locations (54)

1090

AKH - Medical University of Vienna, Vienna

3000

UZ Leuven, Leuven

4000

Centre Hospitalier Universitaire de Liège, Liège

10032

Columbia University Medical Center-New York Presbyterian Hospital, New York

20089

Istituto Clinico Humanitas, Rozzano (MI)

23249

Hunter Holmes McGuire VA Medical Center, Richmond

24105

Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel

30033

Atlanta Center for Gastroenterology, P.C., Decatur

30322

Emory University, Atlanta

30625

Medizinische Hochschule Hannover, Hanover

32803

AdventHealth Orlando, Orlando

33136

University of Miami, Miami

35128

Azienda Ospedaliera Universitaria di Padova, Padua

41013

Hospital Virgen del Rocío, Seville

42415

Yeungnam University Medical Center, Daegu

44106

University Hospitals of Cleveland, Cleveland

45147

Universitätsklinikum Essen AöR, Essen

46026

Hospital Politècnic La Fe, Valencia

48108

Inje University Haeundae Paik Hospital, Busan

52074

Universitätsklinikum Aachen, AöR, Aachen

60637

University of Chicago, Chicago

73112

Digestive Disease Specialists Inc, Oklahoma City

73730

Klinikum Esslingen GmbH, Esslingen am Neckar

76092

Texas Digestive Disease Consultants - Southlake, Southlake

77030

Baylor College of Medicine, Houston

78229

Southern Star Research Institute, LLC, San Antonio

89081

Universitätsklinikum Ulm, Ulm

91054

Universitätsklinikum Erlangen, Erlangen

123423

"Federal State Budgetary Institution State Scientific Center of Coloproctology MOH Russia", Moscow

129110

Reg. Clin. Scientific Research Institute na Vladimiskiy, Moscow

194044

"FSBMEI HPE Military Medical Academy n.a. S.M. Kirov", Saint Petersburg

357502

"The limited liability company Clinic USI 4D", Pyatigorsk

610027

Kirov State Med.Univ. of MoH RF, Kirov

664003

FSB Instit. HC Irkutsk Scient.Cent. Sibirian Branch of Russ. Acad. Scien., Irkutsk

06518

Medical Research Center of Connecticut, LLC, Hamden

A-4010

Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz

R3A 1R9

University of Manitoba - Health Sciences Centre, Winnipeg

N6A 5W9

Victoria Hospital (LHSC), London

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

285-8741

Toho University Sakura Medical Center, Chiba, Sakura

004-0041

Sapporo Tokushukai Hospital, Hokkaido, Sapporo

065-0033

Sapporo Higashi Tokushukai Hospital, Hokkaido, Sapporo

663-8501

Hyogo College of Medicine Hospital, Hyogo, Nishinomiya

892-0846

Sameshima Hospital, Kagoshima, Kagoshima

247-0056

Ofuna Chuo Hospital, Kanagawa, Kamakura

113-8519

Tokyo Medical and Dental University, Tokyo, Bunkyo-ku

108-8642

Kitasato Institute Hospital, Tokyo, Minato-ku

169-0073

Tokyo Yamate Medical Center, Tokyo, Shinjuku

00-632

Health Center of Mother, Child and Youth Sp.z o.o., Warsaw

02-507

Central Clinical Hospital MSWiA, Internal Diseases, Warsaw, Warsaw

S75 2EP

Barnsley Hospital, Barnsley

DN2 5LT

Doncaster Royal Infirmary, Doncaster

SE1 9RT

Guy's Hospital, London

L35 5DR

Whiston Hospital, Prescot

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03482635 - BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis | Biotech Hunter | Biotech Hunter